FDA extends full approval for Merck's Keytruda in 1st-line bladder cancer after mixed adcomm vote
Merck’s accelerated approval for Keytruda in first-line bladder cancer was one of a slate of early nods put under the microscope by an FDA advisory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
